SME Central
Home / Moved to Main Board / Beta Drugs

Beta Drugs: IPO, Share Price and Results Since Listing

Beta Drugs moved from NSE Emerge to the NSE main board on 24 November 2025. For Q2 FY2027 it reported revenue of INR 137.49 crore and a profit after tax of INR 19.28 crore.

Key Facts

Moved to
NSE main board on 24 November 2025
Symbol
BETA
Latest close
INR 1,816.20 on 16 November 2026

Results Filed With NSE

Consolidated figures, INR crore. Change compares with the same period a year earlier.

PeriodRevenueChangeProfit after taxEPS (INR)Filed
Q2 FY2027137.49–19.2816.59main board22 October 2026
Q1 FY2027125.55–16.4914.78main board20 July 2026
Q4 FY202693.96–9.058.93main board14 May 2026
FY2026384.83+6.20%41.4840.92main board14 May 2026
Q3 FY202687.27–8.528.40main board14 February 2026
H1 FY2026203.59–23.9247.38SME platform6 November 2025
H2 FY2025182.05–17.9817.81SME platform15 May 2025
FY2025362.36–42.4242.02SME platform15 May 2025

Promoter Holding

Promoter holding has moved from 66.68% on 30 September 2021 to 58.91% on 30 September 2026 (-7.77 percentage points).

As ofPromotersPublic
30 September 202658.91%41.09%
30 June 202659.10%40.90%
25 May 202659.10%40.90%
31 March 202664.63%35.37%
31 December 202564.90%35.10%
30 September 202566.73%33.27%
30 June 202566.73%33.27%
31 March 202566.73%33.27%
27 March 202566.73%33.27%
31 December 202466.73%33.27%
27 November 202466.73%33.27%
30 September 202466.73%33.27%
30 June 202466.73%33.27%
31 March 202466.73%33.25%
31 December 202366.73%33.26%
30 September 202366.73%33.27%
30 June 202366.73%33.26%
31 March 202366.73%33.27%
31 December 202266.71%33.29%
30 September 202266.71%33.29%
30 June 202266.71%33.29%
31 March 202266.71%33.29%
31 December 202166.71%33.30%
30 September 202166.68%33.31%

Next Board Meeting

19 November 2026: Other business matters

Sources: NSE filings (results XBRL, shareholding pattern, board meetings), NSE daily price files, and IPO records. Prices are not adjusted for bonus issues or splits.